Beneficial effects of enalapril on chlorhexidine digluconate-induced liver peritoneal fibrosis in rats

Chinese Journal of Physiology

Volumn 54, Issue 4, 2011, Pages 225-234

  Lee, Chung Jen ^a   Subeq, Yi Maun ^b   Lee, Ru Ping ^b   Ke, Chen Yen ^c   Lin, Nien Tsung ^c   Hsu, Bang Gee ^d,e  

^a TZU CHI COLLEGE OF TECHNOLOGY   (Taiwan)

^b Department of Nursing ^*  (Taiwan)

^c Institute of Microbiology Immunology and Biochemistry   (Taiwan)

^d TZU CHI UNIVERSITY   (Taiwan)

^e BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Chlorhexidine digluconate; Enalapril; Peritoneal fibrosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; DIANEAL; ENALAPRIL; FIBRONECTIN; GLUCOSE; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; HEART RATE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIVER FIBROSIS; LIVER PROTECTION; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; MICROSCOPY; NONHUMAN; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; UPREGULATION; ANIMAL; LIVER; METABOLISM; PERITONEUM; SPRAGUE DAWLEY RAT;

ANIMALS; ENALAPRIL; LIVER; PERITONEAL FIBROSIS; PERITONEUM; RATS; RATS, SPRAGUE-DAWLEY; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79960322144     PISSN: 03044920     EISSN: 26660059     Source Type: Journal    
DOI: 10.4077/CJP.2011.AMM073     Document Type: Article

References (28)

1. Aroeira, L.S., Aguilera, A., Sánchez-Tomero, J.A., Bajo, M.A., del Peso, G., Jiménez-Heffernan, J.A., Selgas, R. and López-Cabrera, M. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J. Am. Soc. Nephrol. 18: 2004-2013, 2007.
2. Atlas, S.A. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J. Manag. Care Pharm. 13 (8 Suppl B): 9-20, 2007.
3. Augustine, T., Brown, P.W., Davies, S.D., Summers, A.M., and Wilkie, M.E. Encapsulating peritoneal sclerosis: clinical significance and implications. Nephron. Clin. Pract. 111: c149-c154, 2009.
4. Augustyniak, R.A., Maliszewska-Scislo, M., Chen, H., Fallucca, J. and Rossi, N.F. Acute angiotensin-converting enzyme inhibition evokes bradykinin-induced sympathetic activation in diabetic rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293: R2260-R2266, 2007.
5. Carvajal, G., Rodríguez-Vita, J., Rodrigues-Díez, R., Sánchez-López, E., Rupérez, M., Cartier, C., Esteban, V., Ortiz, A., Egido, J., Mezzano, S.A. and Ruiz-Ortega, M. Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. Kidney Int. 74: 585-595, 2008.
6. Duman, S., Günal, A.I., Sen, S., Asçi, G., Ozkahya, M., Terzioglu, E., Akçiçek, F. and Atabay, G. Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution? Perit. Dial. Int. 21: 219-224, 2001.
7. Erman, A., Veksler, S., Gafter, U., Boner, G., Wittenberg, C. and van Dijk, D.J. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat. J. Renin Angiotensin Aldosterone Syst. 5: 146-151, 2004.
8. Faull, R.J. Bad and good growth factors in the peritoneal cavity. Nephrology 10: 234-239, 2005.
9. Fusshoeller, A. Histomorphological and functional changes of the peritoneal membrane during long-term peritoneal dialysis. Pediatr. Nephrol. 23: 19-25, 2008.
10. Ke, C.Y., Lee, C.C., Lee, C.J., Subeq, Y.M., Lee, R.P. and Hsu, B.G. Aliskiren ameliorates chlorhexide digluconate-induced liver peritoneal fibrosis in rats. Eur. J. Clin. Invest. 40: 301-309, 2010.
11. Liu, Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J. Am. Soc. Nephrol. 15: 1-12, 2004.
12. Margetts, P.J., Kolb, M., Galt, T., Hoff, C.M., Shockley, T.R. and Gauldie, J. Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on membrane function. J. Am. Soc. Nephrol. 12: 2029-2039, 2001.
13. Mizobuchi, M., Morrissey, J., Finch, J.L., Martin, D.R., Liapis, H., Akizawa, T. and Slatopolsky, E. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J. Am. Soc. Nephrol. 18: 1796-1806, 2007.
14. Nessim, S.J., Perl, J. and Bargman, J.M. The renin-angiotensinaldosterone system in peritoneal dialysis: is what is good for the kidney also good for the peritoneum? Kidney Int. 78: 23-28, 2010.
15. Noh, H., Ha, H., Yu, M.R., Kim, Y.O., Kim, J.H. and Lee, H.B. Angiotensin II mediates high glucose-induced TGF-β1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit. Dial. Int. 25: 38-47, 2005.
16. Peters, H., Rückert, M., Gaedeke, J., Liefeldt, L., Ketteler, M., Sharma, A.M. and Neumayer, H.H. Angiotensin-converting enzyme inhibition but not beta-adrenergic blockade limits transforming growth factor-beta overexpression in acute normotensive anti-thy1 glomerulonephritis. J. Hypertens. 21: 771-780, 2003.
17. Piepho, R.W. Overview of the angiotensin-converting-enzyme inhibitors. Am. J. Health Syst. Pharm. 57 Suppl 1: S3-S7, 2000.
18. Purohit, V. and Brenner, D.A. Mechanisms of alcohol-induced hepatic fibrosis: a summary of the Ron Thurman Symposium. Hepatology 43: 872-878, 2006.
19. Radek, K.A., Kovacs, E.J. and DiPietro, L.A. Matrix proteolytic activity during wound healing: modulation by acute ethanol exposure. Alcohol. Clin. Exp. Res. 31: 1045-1052, 2007.
20. Ro, Y., Hamada, C., Inaba, M., Io, H., Kaneko, K. and Tomino, Y. Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. Nephrol. Dial. Transplant. 22: 2838-2848, 2007.
21. Sauter, M., Cohen, C.D., Wörnle, M., Mussack, T., Ladurner, R. and Sitter, T. ACE inhibitor and AT1-receptor blocker attenuate the production of VEGF in mesothelial cells. Perit. Dial. Int. 27: 167-172, 2007.
22. Schmidt, D.W. and Flessner, M.F. Pathogenesis and treatment of encapsulating peritoneal sclerosis: basic and translational research. Perit. Dial. Int. 28 Suppl 5: S10-15, 2008.
23. Suga, H., Teraoka, S., Ota, K., Komemushi, S., Furutani, S., Yamauchi, S. and Margolin, S. Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. Exp. Toxicol. Pathol. 47: 287-291, 1995.
24. Toblli, J.E., Stella, I., de Cavanagh, E., Angerosa, M., Inserra, F. and Ferder, L. Enalapril prevents tubulointerstitial lesions by hyperoxaluria. Hypertension 33: 225-231, 1999.
25. Türkay, C., Yönem, O., Arici, S., Koyuncu, A. and Kanbay, M. Effect of angiotensin-converting enzyme inhibition on experimental hepatic fibrogenesis. Dig. Dis. Sci. 53: 789-793, 2008.
26. Witowski, J. and Jörres, A. Preventing peritoneal fibrosis-an ace up our sleeve? Perit. Dial. Int. 25: 25-29, 2005.
27. Yu, L., Border, W.A., Anderson, I., McCourt, M., Huang, Y. and Noble, N.A. Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney Int. 66: 1774-1784, 2004.
28. Yung, S. and Chan, T.M. Preventing peritoneal fibrosis-insights from the laboratory. Perit. Dial. Int. 23 Suppl 2: S37-S41, 2003.